The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma

Uzel, Mehmet Murat; Elgin, Ufuk; Boral, Barış; Çiçek, Muharrem; Şen, Emine; Şener, Burçin; Yılmazbaş, Pelin

doi:10.1007/s00417-018-3923-y

Cited by 13 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, investigators in Iran reported that serum BDNF concentrations decreased more in primary open angle glaucoma (POAG) and NTG patients than in normal patients 14,15 . Recently, similar results were reported from Italy 16 , Turkey 17 , and Russia 18 . BDNF is transported retrogradely from the superior colliculus to the RGCs, and this transport is substantially inhibited by acute IOP elevation 1 .…”

Section: Introductionsupporting

confidence: 80%

“…The cost is about $ 100 / sample if the sample will be measured every time. In this experiment, an attempt was made to examine aqueous humor BDNF levels using the same R&D Human BDNF Immunoassay which Uzel MM et al 17 used. However, we could not measure BDNF in the aqueous humor at all.…”

Section: Discussionmentioning

confidence: 99%

“…Various studies have pointed out the importance of BDNF in glaucoma [14][15][16][17][18][19][20][21][22][23] .…”

Section: Discussionmentioning

confidence: 99%

“…Elevated IOP is the most important known risk factor for glaucoma, but lowering IOP is not always sufficient to halt the progression of the optic neuropathy, particularly in NTG, suggesting the involvement of neuroprotective factors such an BDNF in the pathology of NTG. Although the serum BDNF in glaucoma patients has already been reported [14][15][16][17][18] , there have been no studies performed in northeast Asia, where NTG is the most common type of glaucoma. In this study, the levels of BDNF in the serum of POAG and NTG patients in Japan were evaluated.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum Brain-Derived Neurotrophic Factor in Glaucoma Patients in Japan: An Observational Study

et al. 2020

View full text Add to dashboard Cite

Purpose. The aim of this study was to measure the serum levels of brain-derived neurotrophic factor (BDNF) in primary open angle glaucoma (POAG) and normal tension glaucoma (NTG) patients in Japan. Methods. This was a prospective, observational study that examined serum BDNF levels in 78 patients who underwent cataract surgery or trabeculectomy (27 glaucoma patients and 51 non-glaucoma cataract patients as controls). The patients' age was 68.8 ± 11.1 years (mean ± standard deviation; range 35-86 years). The number of patients with POAG and NTG was 16 and 11, respectively. The diagnosis of POAG was done by intraocular pressure measurement, gonioscopy, optic nerve head change, and the presence of a visual field defect. Results. The serum BDNF concentration was significantly lower in the glaucoma group, including both POAG and NTG, than in the control group (7.2 ± 3.6 ng/mL vs. 12.2 ± 9.3 ng/mL, p=0.004). The serum BDNF concentration was lower in the early phase than in the moderate phases of glaucoma. There was no correlation between the serum BDNF concentration and age. When the NTG and POAG patient groups were compared, the serum BDNF concentration was lower in NTG patients than in POAG patients. No significant correlations were found between glaucoma parameters, including optical coherence tomography and visual field defects, and the serum BDNF concentration. Conclusion. This is the first study to have investigated serum BDNF concentrations in glaucoma patients in Japan. Further investigations are needed to evaluate the role of BDNF as a potential biomarker of glaucoma.

show abstract

Section: Introductionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

“…Various studies have pointed out the importance of BDNF in glaucoma [14][15][16][17][18][19][20][21][22][23] .…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Brain-Derived Neurotrophic Factor in Glaucoma Patients in Japan: An Observational Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We chose to develop and test a novel gene therapy construct involving brain-derived neurotrophic factor (BDNF) and its cognate receptor, tropomyosin-related receptor kinase-B (TrkB) 8 – 10 , whose expression and activation are impaired in rodent 11 – 16 , dog 17 , and primate 18 models of glaucoma. There is also increasing evidence of reduced BDNF and TrkB signaling in human glaucoma 19 – 22 , including patients with normal tension glaucoma 19 .…”

Section: Introductionmentioning

confidence: 99%

Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling

et al. 2018

View full text Add to dashboard Cite

Previous studies have demonstrated that intravitreal delivery of brain-derived neurotrophic factor (BDNF) by injection of recombinant protein or by gene therapy can alleviate retinal ganglion cell (RGC) loss after optic nerve injury. BDNF gene therapy can improve RGC survival in experimental models of glaucoma, the leading cause of irreversible blindness worldwide. However, the therapeutic efficacy of BDNF supplementation alone is time limited at least in part due to BDNF receptor downregulation. Tropomyosin-related receptor kinase-B (TrkB) downregulation has been reported in many neurological diseases including glaucoma, potentially limiting the effect of sustained or repeated BDNF delivery.Here, we characterize a novel adeno-associated virus (AAV) gene therapy (AAV2 TrkB-2A-mBDNF) that not only increases BDNF production but also improves long-term neuroprotective signaling by increasing expression of the BDNF receptor (TrkB) within the inner retina. This approach leads to significant and sustained elevation of survival signaling pathways ERK and AKT within RGCs over 6 months and avoids the receptor downregulation which we observe with treatment with AAV2 BDNF alone. We validate the neuroprotective efficacy of AAV2 TrkB-2A-mBDNF in a mouse model of optic nerve injury, where it outperforms conventional AAV2 BDNF or AAV2 TrkB therapy, before showing powerful proof of concept neuroprotection of RGCs and axons in a rat model of chronic intraocular pressure (IOP) elevation. We also show that there are no adverse effects of the vector on retinal structure or function as assessed by histology and electroretinography in young or aged animals. Further studies are underway to explore the potential of this vector as a candidate for progression into clinical studies to protect RGCs in patients with glaucoma and progressive visual loss despite conventional IOP-lowering treatment.

show abstract

Serum and aqueous humor levels of brain-derived neurotrophic factor in patients with primary open-angle glaucoma and normal-tension glaucoma

Wan

Kim

2021

Int Ophthalmol

View full text Add to dashboard Cite

This study designed to compare the levels of brain-derived neurotrophic factor (BDNF) in the serum and aqueous humor (AH) of patients with primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). MethodsThis prospective, observational study consists of 30 patients with POAG, 30 patients with NTG, and 30 healthy controls. The serum and AH BDNF levels were assessed using an enzyme-linked immunosorbent assay. ResultsBDNF levels in serum and AH were markedly lower in the glaucoma groups (POAG and NTG) than in the control group (p < 0.05). When comparing the NTG and POAG groups, the average serum BDNF level was signi cantly lower in the NTG group than in the POAG group (p < 0.05). The difference in the mean BDNF levels in AH between the POAG and NTG groups was not statistically signi cant. (p = 0.538). ConclusionWe con rmed that serum BDNF levels were lower in patients with NTG than in those with POAG. BDNF could be a causative systemic biomarker in NTG.

show abstract

The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma

Abstract: Trabeculectomy was found to have a positive effect on serum BDNF levels in POAG cases.

Cited by 13 publications

References 24 publications

Serum Brain-Derived Neurotrophic Factor in Glaucoma Patients in Japan: An Observational Study

Serum Brain-Derived Neurotrophic Factor in Glaucoma Patients in Japan: An Observational Study

Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling

Serum and aqueous humor levels of brain-derived neurotrophic factor in patients with primary open-angle glaucoma and normal-tension glaucoma

Contact Info

Product

Resources

About